Project Grant R01AT013875
- The National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $170,640 on April 17, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The award funds development and feasibility testing of TOPMED (Toolkit for Optimal Pain Management in the Emergency Department), a mind-body intervention designed to reduce pain...
- Federal Grant Award Summary The Spaulding Rehabilitation Hospital Corporation received a $125,625 Project Grant (R21 mechanism) awarded on August 15, 2025, under the Trans-NIH Research Support program (CFDA 93.310) from the National Institutes of Health (NIH) Office of the Director. The project, which will conclude on July 31, 2027, delivers a research investigation examining the patient-clinician relationship in fibromyalgia treatment through Theory of Mind (ToM) training and...
- The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health under the Department of Health and Human Services, awarded the University of Maryland, Baltimore $4.929 million on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate a multi-omic, psychosocial, and environmental model of individual differences in pain and placebo responses. The project investigates chronic pain conditions, particularly...
- The National Center for Complementary and Integrative Health awarded Massachusetts General Hospital (operating as The General Hospital Corporation) a Cooperative Agreement totaling $1,258,356 on August 5, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). Performance runs through July 31, 2027, with work performed in Boston, Massachusetts. The award funds the Toolkit for Optimal Recovery After Orthopedic Injury (TOR), a multi-site efficacy...
- The National Center for Complementary and Integrative Health (NCCIH), a component of the Department of Health and Human Services National Institutes of Health, awarded $407,856 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on August 1, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The recipient will conduct research examining how alpha-frequency transcranial alternating current stimulation (tACS) targeting...
- The National Center for Complementary and Integrative Health (NCCIH) at the Department of Health and Human Services awarded The Regents of the University of California, San Francisco $601,259 on April 17, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to assess the multi-site feasibility of an integrated whole-body hyperthermia and cognitive behavioral therapy intervention for major depressive disorder. The award funds a three-site feasibility...
- The National Institutes of Health National Center for Complementary and Integrative Health awarded Mayo Clinic Jacksonville $780,208 on September 1, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to conduct a randomized controlled trial evaluating the efficacy of a mobile app-based mindfulness intervention for managing chronic pain in persons with spinal cord injury. The study addresses a clinical gap: chronic pain affects 65–85% of people...
- The National Institute of Neurological Disorders and Stroke awarded $462,000 to Icahn School of Medicine at Mount Sinai on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and conduct a proof-of-concept study of a videoconference-based hypnosis intervention for pain management in women with metastatic breast cancer. The research addresses pain management in the population of over 168,000 women living with metastatic breast cancer in the United...
- The National Center for Complementary and Integrative Health, part of the Department of Health and Human Services National Institutes of Health, awarded Duke University $444,125 on August 13, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to test the feasibility and acceptability of a psychological support and resource navigator program for orthopedic patients with high-impact chronic musculoskeletal pain. The navigator program addresses the...
- The National Center for Complementary and Integrative Health awarded $831,984 to Scripps Research Institute on April 17, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to investigate the neural mechanisms by which the interoceptive system co-regulates emotional and autonomic responses. The research addresses the coupling between emotion and autonomic control—phenomena such as anxiety elevating blood pressure, stress inducing sighing, and...
The National Center for Complementary and Integrative Health awarded The Spaulding Rehabilitation Hospital Corporation $732,927 on September 1, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213, Project Grant R01AT013875) to investigate the neurobiology of pain catastrophizing in burn survivors and identify how cognitive-behavioral therapy modulates the neural circuitry underlying catastrophizing. The research identifies catastrophizing—negative cognitive-emotional processing—as a critical mechanism in chronic burn-injury pain. The funded work will establish the association between brain processing of catastrophizing and individual differences in pain intensity and interference among burn survivors, evaluate whether cognitive-behavioral therapy produces greater improvement in pain and catastrophizing compared to control intervention and reduces brain response to catastrophizing cues, and determine whether baseline brain fMRI response to catastrophizing cues predicts long-term pain outcomes. The study aims to foster personalization of therapy by identifying objective catastrophizing-linked biomarkers that may serve as therapeutic targets. Work is performed at Charlestown, Massachusetts, with a period of performance from September 1, 2026, through June 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $732.9k | 9/1/26 |